Sirolimus for Graves' Orbitopathy (GO)

Graves Ophthalmopathy Clinical Trial

— SIRGO  

Official title:

A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04598815
• Other study ID #: SIRGO
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2023
• Est. completion date: May 31, 2025

Study information

• Verified date: March 2023
• Source: University of Pisa
• Contact: Michele Marinò, MD
• Phone: +39050997346
• Email: michele.marino[@]med.unipi.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast proliferation and release of glycosaminoglycans. The current treatments available, especially glucocorticoids, are not effective in all patients. Two cases of patients with GO treated with Sirolimus have been reported with an excellent response to the drug.

The rationale for the use of Sirolimus lies in its mechanisms of action. Sirolimus is able to inhibit T-cell activation as well as fibroblast proliferation. In addition, acts indirectly on the Insulin-Like Growth Factor-1 (IGF-1) pathway, and recent clinical trials have shown that a monoclonal antibody against the IGF-1 receptor (Teprotumumab) is effective in patients with GO. Thus, Sirolimus could be used in GO as monotherapy in patients with GO.

The aim of the present drug vs standard treatment, open-label, randomized clinical trial is to evaluate the efficacy of Sirolimus in patients with moderately severe, active GO.

54 patients (27 per group) will be randomized into two groups, A and B. Patients in group A will receive Sirolimus for 12 weeks. Patients in group B will receive methylprendnisolone for 12 weeks.

The primary objective of the study is the response of GO at 24 weeks based on a composite evaluation. The secondary Objectives will be: 1) the response of of GO at 12, 36 and 48 weeks; 2) Relapse of GO at 36 and 48 weeks (worsening compared with the 24-week evaluation); 3) The reduction of proptosis at 12, 24, 36 and 48 weeks (proportion of patients with a reduction of proptosis of at least 2 mm); 4) Reduction of the GO clinical activity score (CAS) at 12, 24, 36 and 48 weeks; 5) Quality of life (Qol) at 12, 24, 36 and 48 weeks.

The safety objectives will be adverse events, adverse drug reactions, unexpected adverse reaction, suspected unexpected adverse reactions and death, across the study and at 12, 24, 36 and 48 weeks.

Description:

Study Design Phase II, randomized, adaptive, superiority, open-label, single-center, pilot clinical trial.

Fifty-four patients with moderate-to-severe and active GO will be randomized into two intervention groups, A and B, with a ratio of 1: 1. Subjects assigned to group A will receive Sirolimus for 12 weeks. Patients assigned to group B will receive a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions. This treatment scheme is the clinical standard and patients would be treated with methylprednisolone in any case, even if they did not accept to participate to the study.

Enrollment duration: 24 months Study duration: 36 months Tentative start of trial: July 1st 2022

Study Population Fifty-four patients with Graves' disease and GO will be recruited during the routine clinical activity carried out at the Endocrinology Unit II of AOUP, which is a tertiary referral center for thyroid diseases.

Study Timeline

• Screening visit (2-6 weeks before the first visit)

• 1st (baseline) visit - (Time 0): randomization and administration of the first dose of trial agent

• Treatment period (week 1-week 12): daily administration of the trial agent (Sirolimus) or weekly administration of the standard treatment (methylprednisolone)

• Methylprednisolone treatment period and treatment visits (week 2-week 13); weekly methylprednisolone administrations (week 2-week 13)

• Safety visits (week 3, 5, 7, 9, 11)

• 2nd visit (week 12)

• 3rd visit (week 24)

• 4th visit (week 36)

• 5th visit (week 48)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 54
• Est. completion date: May 31, 2025
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients willing and capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

2. A diagnosis of Graves' disease based on the presence of hyperthyroidism (either untreated or treated with antithyroid drugs) associated with detectable anti-thyrotropic hormone (TSH) receptor autoantibodies (TRAb). Patients must be euthyroid under control on stable medical regimen and every effort will be made to maintain the euthyroid status for the entire duration of the clinical trial

3. A moderate-to-severe GO, defined as the presence of at least one of the following criteria: an exophthalmos =2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction =2 mm

4. Active GO: CAS (4) =2 out of 7 points in the most affected eye

5. GO duration =18 months

6. Male and female patients of age: 18-75 years

7. Creatinine values within the reference range

8. Indexes of liver function (AST, ALT, ?GT, alkaline phosphatase, total and direct bilirubin) within the normal range

9. Normal blood count, absence of diseases of hematopoiesis

10. Women of childbearing potential (WOCBP, namely not in menopause or in menopause since less than two years; in all other instances women will be considered as non-WOCBP) and men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year (as indicated in Appendix) for at least 6 and 7,5 months, respectively, after the last dose of the investigational drug (see also 2014_09_HMA_CTFG_Contraception.pdf, namely the "2014 CTFG Reccommendtions related to contraception and pregnancy testing in clinical trials")

11. Compliant patients, regular follow-up possible

Exclusion Criteria:

1. Optic neuropathy

2. Treatment with glucocorticoids, other immunosuppressive drugs or selenium for the last three months

3. Previous surgery or radiotherapy for GO

4. Radioiodine treatment for hyperthyroidism over the last 3 months, as it can affect GO

5. Contraindications to Sirolimus: hypersensitivity to the active substance or to any of the excipients; use of medications interfering with the pharmacokinetic and/or pharmacodynamic properties of rapamycin (e.g. CYP3A4 inhibitors or inducers; see "prohibited therapies")

6. Contraindications to GC: hypersensitivity to the active substance or to any of the excipients; uncontrolled hypertension, uncontrolled diabetes; history of peptic ulcer; urinary infections, glaucoma, systemic fungal infections, systemic infections unless appropriate therapy is employed, idiopathic thrombocytopenic purpura, cerebral edema associated with malaria.

7. Use of medications interfering with GC or increasing the risk of GC-related adverse events (see prohibited therapies)

8. Pregnant or lactating females as determined by positive serum or urine HCG test at baseline

9. Acute or chronic liver disease

10. Relevant malignancies

11. Current and/or previous diseases of hematopoiesis

12. Recent (=1 year) history of alcoholism or drug abuse

13. Mental illness that prevent patients from comprehensive, written informed consent

Related Conditions & MeSH terms

• Eye Diseases
• Graves Ophthalmopathy

Intervention

Drug:
• Sirolimus
Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks. Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g.

Locations

Country	Name	City	State
Italy	Ospedale Cisanello-Endocrinology II	Pisa

Sponsors (1)

Lead Sponsor	Collaborator
University of Pisa

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GO overall response	Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions =8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.	24 weeks
Secondary	GO overall response	Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions =8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.	12 weeks
Secondary	GO overall response	Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions =8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.	36 weeks
Secondary	GO overall response	Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions =8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.	48 weeks
Secondary	GO relapse	Percentage of subjects with worsening of GO in comparison with the 24 week evaluation. Worsening is defined as change in two of the following in at least one eye (compared to baseline): a) Worsening in CAS by at least 1 point; b) Worsening of exophthalmos (>2 mm); c) Worsening of lid aperture (>2 mm); d) Worsening of eye ductions =8 degrees; d) Worsening of visual acuity by at least 0.2/1	36 weeks
Secondary	GO relapse	Percentage of subjects with worsening of GO in comparison with the 24 week evaluation. Worsening is defined as change in two of the following in at least one eye (compared to baseline): a) Worsening in CAS by at least 1 point; b) Worsening of exophthalmos (>2 mm); c) Worsening of lid aperture (>2 mm); d) Worsening of eye ductions =8 degrees; d) Worsening of visual acuity by at least 0.2/1	48 weeks
Secondary	Change in exophthalmos	Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye	12 weeks
Secondary	Change in exophthalmos	Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye	24 weeks
Secondary	Change in exophthalmos	Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye	36 weeks
Secondary	Change in exophthalmos	Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye	48 weeks
Secondary	Change in the clinical activity score (CAS)	Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye	12 weeks
Secondary	Change in the clinical activity score (CAS)	Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye	24 weeks
Secondary	Change in the clinical activity score (CAS)	Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye	36 weeks
Secondary	Change in the clinical activity score (CAS)	Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye	48 weeks
Secondary	Change in quality of life	Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)	12 weeks
Secondary	Change in quality of life	Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)	24 weeks
Secondary	Change in quality of life	Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)	36 weeks
Secondary	Change in quality of life	Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)	48 weeks
Secondary	Percentage of adverse events	Percentage of adverse events, adverse drug reactions, death across the study period	48 weeks